Checkpoint inhibition in pediatric hematologic malignancies.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Immune surveillance naturally eliminates cancer, but inhibitory receptors and ligands promote cancer evasion.
• Immune checkpoint inhibitors (ICIs) are a novel cancer immunotherapy targeting these regulators.
• Approved ICIs include ipilimumab (anti-CTLA-4) for melanoma; others targeting PD-1, PD-L1, and LAG-3 are under investigation.

Purpose of the Study:

• To review the current landscape of immune checkpoint inhibitors in cancer therapy.
• To highlight the efficacy and safety of ICIs in adult solid tumors and hematological malignancies.
• To discuss the limited pediatric experience and upcoming trials in childhood leukemia.

Main Methods:

• Review of clinical trial data and literature on immune checkpoint inhibitors.
• Analysis of efficacy and safety profiles of CTLA-4 and PD-1 inhibitors.
• Examination of pediatric applications and ongoing clinical trials.

Main Results:

• ICIs have shown promising efficacy and safety in adult solid tumors and some hematological malignancies.
• CTLA-4 and PD-1 inhibitors are generally well-tolerated but can cause immune-related adverse events (irAEs).
• Pediatric experience is limited, primarily to Hodgkin's and non-Hodgkin's lymphoma.

Conclusions:

• Immune checkpoint inhibitors represent a significant advance in cancer immunotherapy for adults.
• Further research and clinical trials are needed to expand their use in pediatric hematological malignancies, such as acute myeloid leukemia (AML).
• Understanding and managing irAEs is crucial for successful ICI therapy.